Peel Hunt reaffirmed their buy rating on shares of Oxford BioMedica (LON:OXB) in a report issued on Monday. The brokerage currently has a GBX 13 ($0.18) target price on the biopharmaceutical company’s stock.
Shares of Oxford BioMedica (LON OXB) opened at GBX 10.58 ($0.14) on Monday. Oxford BioMedica has a 52 week low of GBX 3.77 ($0.05) and a 52 week high of GBX 11.54 ($0.16).
In other Oxford BioMedica news, insider Lorenzo Tallarigo acquired 30,861 shares of the firm’s stock in a transaction on Thursday, November 23rd. The stock was bought at an average cost of GBX 9 ($0.12) per share, for a total transaction of £2,777.49 ($3,766.60). Over the last quarter, insiders have acquired 90,662 shares of company stock valued at $815,958.
TRADEMARK VIOLATION NOTICE: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.com-unik.info/2018/01/11/oxford-biomedica-oxb-receives-buy-rating-from-peel-hunt.html.
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.